The RPE cells tend to be the first ever to die off in SMD and AMD, which really is a contributor to the patient’s loss of vision. Several years ago ACT scientists derived RPE cells from human embryonic stem cells successfully. Later, they were in a position to derive them from cells developed from the business’s proprietary blastomere technology that will not destroy the embryo. Subsequent studies found that the cells could regain vision in animal types of macular degeneration.Seven brand-new Ointment products the business launched following the first one fourth of 2010 contributed incremental sales of $0.3 million through the initial quarter of 2011, which partially offset the entire Ointments sales decrease. Product sales of Patches declined 41.9 percent year-over-year to $4.8 million, or approximately 16.8 percent of total sales in the first quarter of 2011, reflecting lower sales of the Company’s TREATMENT Patch and Asthma Patch items after the termination of an integral distribution relationship during the third quarter of 2010. Sales of Wash Liquids increased 206.6 percent year-over-yr to $2.7 million, or 9 approximately.5 percent of total sales in the first quarter of 2011, mainly powered by higher sales of the Company’s Metronidazole and Chlorhexidine Washing Fluids after adding a fresh distributor in the second quarter of 2010.